Ardelyx Stock Earnings Estimates Decreased by HC Wainwright

Ardelyx, Inc. (NASDAQ:ARDX) – HC Wainwright lowered their FY2028 earnings per share estimates for Ardelyx in a research note issued on Wednesday, November 4th. HC Wainwright analyst M. Caufield now expects that the biopharmaceutical company will earn $0.58 per share for the year, down from their previous estimate of $0.66. HC Wainwright has a “Buy” rating and a $13.00 price target on the stock. The consensus estimate for Ardelyx’s current full-year earnings is ($0.20) per share.

Ardelyx (NASDAQ:ARDX) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The business had revenue of $120.88 million for the quarter, compared to analyst estimates of $121.03 million. Ardelyx had a negative return on equity of 35.82% and a negative net margin of 11.85%. Ardelyx’s revenue was up 34.3% compared to the same quarter last year. During the same period last year, the business earned ($0.08) EPS.

A number of other equities research analysts have also issued reports on ARDX. Wedbush reaffirmed an “outperform” rating and issued a $9.00 price target on shares of Ardelyx in a research report on Tuesday, August 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of Ardelyx in a research report on Friday, September 25th. Zacks Research upgraded Ardelyx from a “strong sell” rating to a “hold” rating in a research note on Friday, October 16th. TD Cowen decreased their target price on Ardelyx from $13.00 to $10.00 and set a “buy” rating for the company in a research note on Friday, August 7th. Finally, BTIG Research lowered their price target on Ardelyx from $17.00 to $14.00 and set a “buy” rating for the company in a report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.90.

Ardelyx Price Performance

ARDX stock opened at $3.29 on Thursday. Ardelyx has a 12-month low of $2.95 and a 12-month high of $8.40. The business’s fifty day moving average price is $3.39 and its 200 day moving average price is $5.28. The company has a market capitalization of $819.83 million, a PE ratio of -14.95 and a beta of 0.79. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.69.

Institutional Trading of Ardelyx

Several institutional investors and hedge funds have recently bought and sold shares of ARDX. BlackRock Inc. acquired a new stake in shares of Ardelyx during the 2nd quarter valued at approximately $119,874,000. Jupiter Topco LLC bought a new stake in shares of Ardelyx during the 2nd quarter valued at about $27,043,000. AIGH Capital Management LLC bought a new stake in shares of Ardelyx during the 2nd quarter valued at about $16,320,000. Bank of America Corp DE boosted its stake in Ardelyx by 5.8% in the first quarter. Bank of America Corp DE now owns 2,336,994 shares of the biopharmaceutical company’s stock valued at $13,999,000 after acquiring an additional 128,301 shares during the period. Finally, Eversept Partners LP grew its holdings in shares of Ardelyx by 30.0% during the first quarter. Eversept Partners LP now owns 2,229,446 shares of the biopharmaceutical company’s stock valued at $13,354,000 after purchasing an additional 514,317 shares during the last quarter. Institutional investors and hedge funds own 58.92% of the company’s stock.

Insider Buying and Selling

In other Ardelyx news, CEO Michael Raab sold 58,574 shares of the company’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $3.86, for a total value of $226,095.64. Following the transaction, the chief executive officer directly owned 1,619,792 shares of the company’s stock, valued at $6,252,397.12. This represents a 3.49% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Laura A. Williams sold 10,739 shares of Ardelyx stock in a transaction on Friday, August 21st. The stock was sold at an average price of $3.86, for a total transaction of $41,452.54. Following the completion of the sale, the insider owned 367,456 shares of the company’s stock, valued at approximately $1,418,380.16. This trade represents a 2.84% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 126,059 shares of company stock valued at $486,588 over the last three months. Company insiders own 5.30% of the company’s stock.

Ardelyx News Summary

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: Q3 product revenue rose 19% year over year to $125.5 million. IBSRELA revenue increased 23% to $96.3 million, and Ardelyx reported break-even EPS versus analyst expectations for a loss of $0.03. The company maintained its full-year IBSRELA revenue outlook of $350 million to $370 million. Ardelyx Q3 2026 results
• Positive Sentiment: Ardelyx completed enrollment ahead of schedule in the Phase 3 ACCEL trial of IBSRELA for chronic idiopathic constipation. Topline results are expected in the second half of 2027, providing a potential future growth opportunity. ACCEL trial enrollment announcement
• Neutral Sentiment: The company had $285.3 million in cash, cash equivalents and investments at quarter-end, providing resources to support operations and development. Ardelyx Q3 2026 results
• Negative Sentiment: Several law firms publicized a pending securities class action and the November 16 lead-plaintiff deadline. The suit alleges Ardelyx’s statements about patient access and sales prospects for IBSRELA and XPHOZAH did not adequately reflect payer prior-authorization and step-edit barriers that allegedly slowed new-patient starts. These are allegations, not proven findings; the litigation may create uncertainty and costs. Class-action deadline notice

Ardelyx Company Profile

Ardelyx, Inc is a biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal and cardiorenal diseases. The company’s platform is centered on regulating ion transport in the gut, with the goal of addressing conditions that are inadequately served by existing treatments.

Ardelyx’s marketed products include IBSRELA (tenapanor), an oral treatment for adults with irritable bowel syndrome with constipation, and XPHOZAH (tenapanor), a therapy designed to reduce serum phosphorus in adults with chronic kidney disease on dialysis who have an inadequate response to, or are intolerant of, phosphate binders.